Journal
NATURE CHEMICAL BIOLOGY
Volume 14, Issue 8, Pages 764-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41589-018-0090-8
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [SFB 749, SFB 1116, TP A01]
- Center for Integrated Protein Science Munich (CIPSM)
- DFG [SPP1926]
- BMBF (DZHK) [FKZ: 81 x 2800159]
- Diabetes UK R.D. Lawrence [12/0004431]
- EFSD/Novo Nordisk Rising Star Fellowships
- Wellcome Trust Institutional Support Award
- COMPARE Primer
- MRC Project [MR/N00275X/1]
- ERC Starting Grants (OptoBETA) [715884]
- Deutsche Telekom Stiftung
- LMUMentoring program
- NSERC, Canada [GRPIN-2014-04894]
- Russian Science Foundation [17-15-01292]
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [GRK1873, SA 1785/7-1, SA 1785/9-1]
- Russian Science Foundation [17-15-01292] Funding Source: Russian Science Foundation
- MRC [MR/N00275X/1] Funding Source: UKRI
Ask authors/readers for more resources
L-type Ca2+ channels (LTCCs) play a crucial role in excitation-contraction coupling and release of hormones from secretory cells. They are targets of antihypertensive and antiarrhythmic drugs such as diltiazem. Here, we present a photoswitchable diltiazem, FHU-779, which can be used to reversibly block endogenous LTCCs by light. FHU-779 is as potent as diltiazem and can be used to place pancreatic beta-cell function and cardiac activity under optical control.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
